-
Je něco špatně v tomto záznamu ?
Seroprevalence of antibodies to varicella-zoster virus in Madrid (Spain) in the absence of vaccination
Napoleon Perez-Farinos, Luis Garcia-Comas, Rosa Ramirez-Fernandez, Juan-Carlos Sanz, Dolores Barranco, Cristina Garcia-Fernandez, Maria Ordobas
Jazyk angličtina Země Česko
Digitální knihovna NLK
Plný text - Článek
Číslo
Ročník
Zdroj
Zdroj
NLK
Free Medical Journals
od 2004
Medline Complete (EBSCOhost)
od 2006-03-01 do Před 6 měsíci
ROAD: Directory of Open Access Scholarly Resources
od 1993
- MeSH
- aktivní imunita genetika účinky léků MeSH
- ELISA metody využití MeSH
- interpretace statistických dat MeSH
- séroepidemiologické studie MeSH
- vakcinace metody využití MeSH
- virus varicella zoster imunologie MeSH
- zkřížené reakce imunologie MeSH
- Geografické názvy
- Španělsko MeSH
Objective: to ascertain the seroprevalence of antibodies to varicella-zoster virus in the Madrid population prior to the introduction of vaccination. Study design: Cross-sectional antibody seroprevalence study. Methods: Population: persons aged 2 to 40 years in Madrid. Field work: September 1999 to April 2000. Data were collected on demographic and socio-economic variables and on a number of exposures. IgG antibodies were determined using Enzyme Linked ImmunoSorbent Assay (ELISA), and antibody prevalence broken down by age group. Logistic regression was used to analyse the association between the presence of antibodies and the respective study variables. The results were compared against those of an earlier seroprevalence survey in Madrid (1993). Results: A total of 2,131 subjects were included, with a non-response rate of 20.4%. Antibody prevalence was estimated at 90.2%; the 90% mark was reached at 11 years of age and almost 100% of adults presented with antibodies. In the case of children, school attendance associated with the presence of antibodies. No significant differences were observed vis-a-vis the results of the earlier survey. Conclusions: The seroprevalence profile coincides with those of other Spanish regions and European countries, and remains stable over time. Antibody presence rises sharply in children from aged 2 years to adolescence. Further seroprevalence studies are called for to study the disease trend and assess preventive measures.
Citace poskytuje Crossref.org
Lit.: 31
- 000
- 03418naa 2200457 a 4500
- 001
- bmc07509236
- 003
- CZ-PrNML
- 005
- 20111210123439.0
- 008
- 080923s2008 xr e eng||
- 009
- AR
- 024 7_
- $a 10.21101/cejph.a3454 $2 doi
- 035 __
- $a (PubMed)18459480
- 040 __
- $a ABA008 $b cze $c ABA008 $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a xr
- 100 1_
- $a Perez-Farinos, Napoleon
- 245 10
- $a Seroprevalence of antibodies to varicella-zoster virus in Madrid (Spain) in the absence of vaccination / $c Napoleon Perez-Farinos, Luis Garcia-Comas, Rosa Ramirez-Fernandez, Juan-Carlos Sanz, Dolores Barranco, Cristina Garcia-Fernandez, Maria Ordobas
- 314 __
- $a Epidemiology Department. Madrid Public Health Institute, Madrid
- 504 __
- $a Lit.: 31
- 520 9_
- $a Objective: to ascertain the seroprevalence of antibodies to varicella-zoster virus in the Madrid population prior to the introduction of vaccination. Study design: Cross-sectional antibody seroprevalence study. Methods: Population: persons aged 2 to 40 years in Madrid. Field work: September 1999 to April 2000. Data were collected on demographic and socio-economic variables and on a number of exposures. IgG antibodies were determined using Enzyme Linked ImmunoSorbent Assay (ELISA), and antibody prevalence broken down by age group. Logistic regression was used to analyse the association between the presence of antibodies and the respective study variables. The results were compared against those of an earlier seroprevalence survey in Madrid (1993). Results: A total of 2,131 subjects were included, with a non-response rate of 20.4%. Antibody prevalence was estimated at 90.2%; the 90% mark was reached at 11 years of age and almost 100% of adults presented with antibodies. In the case of children, school attendance associated with the presence of antibodies. No significant differences were observed vis-a-vis the results of the earlier survey. Conclusions: The seroprevalence profile coincides with those of other Spanish regions and European countries, and remains stable over time. Antibody presence rises sharply in children from aged 2 years to adolescence. Further seroprevalence studies are called for to study the disease trend and assess preventive measures.
- 650 _2
- $a séroepidemiologické studie $7 D016036
- 650 _2
- $a virus varicella zoster $x imunologie $7 D014645
- 650 _2
- $a aktivní imunita $x genetika $x účinky léků $7 D007110
- 650 _2
- $a vakcinace $x metody $x využití $7 D014611
- 650 _2
- $a zkřížené reakce $x imunologie $7 D003429
- 650 _2
- $a ELISA $x metody $x využití $7 D004797
- 650 _2
- $a interpretace statistických dat $7 D003627
- 651 _2
- $a Španělsko $7 D013030
- 700 1_
- $a Garcia-Comas, Luis
- 700 1_
- $a Ramirez-Fernandez, Rosa
- 700 1_
- $a Sanz, Juan-Carlos
- 700 1_
- $a Barranco, Dolores
- 700 1_
- $a Garcia-Fernandez, Cristina
- 700 1_
- $a Ordobas, Maria
- 773 0_
- $w MED00001083 $t Central European journal of public health $g Roč. 16/52, č. 1 (2008), s. 41-44 $x 1210-7778
- 856 41
- $u http://www.szu.cz/svi/cejph/archiv/2008-1-10.pdf $y plný text volně přístupný
- 910 __
- $a ABA008 $b B 1829 $c 562 $y 1
- 990 __
- $a 20080923083420 $b ABA008
- 991 __
- $a 20081217142030 $b ABA008
- 999 __
- $a ok $b bmc $g 624829 $s 477264
- BAS __
- $a 3
- BMC __
- $a 2008 $b 16 $c 1 $d 41-44 $i 1210-7778 $m Central European Journal of Public Health $x MED00001083
- LZP __
- $a 2008-31/vtal